Ajanta Pharma Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Net Sales

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

1,186.64

1,144.92

Other Operating Income

0.00

Total Operating income

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

1,186.64

1,144.92

Raw Material Cost

235.07

217.60

207.08

190.96

210.14

207.09

238.41

Purchase of Finished goods

53.55

53.26

51.63

80.18

78.55

45.79

45.28

(Increase) / Decrease In Stocks

-2.36

45.95

17.17

12.28

-30.88

8.80

-15.84

Employee Cost

330.52

317.01

302.90

279.78

265.17

260.96

283.78

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

375.82

392.08

372.52

310.06

302.32

352.83

262.94

Total Expenditure (Excl Depreciation)

992.60

1,025.90

951.30

873.26

825.30

875.47

814.57

Operating Profit (PBDIT) excl Other Income

382.24

327.83

351.35

297.15

320.83

311.17

330.35

Other Income

24.97

59.34

26.33

18.11

30.44

19.48

26.47

Operating Profit (PBDIT)

407.21

387.17

377.68

315.26

351.27

330.65

356.82

Interest

5.10

3.39

5.26

6.07

7.91

6.02

0.73

Exceptional Items

0.00

Gross Profit (PBDT)

402.11

383.78

372.42

309.19

343.36

324.63

356.09

Depreciation

43.51

42.97

41.29

39.78

35.97

34.39

33.97

Profit Before Tax

358.60

340.81

331.13

269.41

307.39

290.24

322.12

Tax

84.83

80.62

75.79

44.15

74.51

73.76

76.35

Provisions and contingencies

0.00

Profit After Tax

273.77

260.19

255.34

225.26

232.88

216.48

245.77

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

273.77

260.19

255.34

225.26

232.88

216.48

245.77

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

273.77

260.19

255.34

225.26

232.88

216.48

245.77

Equity Capital

25.07

Face Value

2.0

Reserves

0.00

Earnings per share (EPS)

21.84

20.76

20.37

17.97

18.58

17.27

19.61

Diluted Earnings per share

21.91

20.82

20.43

18.0

18.59

17.26

19.53

Operating Profit Margin (Excl OI)

27.8%

24.22%

26.97%

25.39%

27.99%

26.22%

28.85%

Gross Profit Margin

29.25%

28.35%

28.59%

26.42%

29.96%

27.36%

31.1%

PAT Margin

19.91%

19.22%

19.6%

19.25%

20.32%

18.24%

21.47%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Dec 2025 is 19.95% vs 3.71% in Dec 2024

Consolidate Net Profit

YoY Growth in quarter ended Dec 2025 is 17.56% vs 10.88% in Dec 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Dec 2025 is 19.14% vs 2.15% in Dec 2024

Interest

YoY Growth in quarter ended Dec 2025 is -35.52% vs 217.67% in Dec 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024

Compare Quarterly Results Of Ajanta Pharma With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

1,374.84

2,556.50

-1,181.66

-46.22%

Other Operating Income

0.00

Total Operating income

1,374.84

2,556.50

-1,181.66

-46.22%

Raw Material Cost

235.07

569.87

-334.80

-58.75%

Purchase of Finished goods

53.55

126.83

-73.28

-57.78%

(Increase) / Decrease In Stocks

-2.36

84.94

-87.30

-102.78%

Employee Cost

330.52

537.94

-207.42

-38.56%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

375.82

692.00

-316.18

-45.69%

Total Expenditure (Excl Depreciation)

992.60

2,011.58

-1,018.98

-50.66%

Operating Profit (PBDIT) excl Other Income

382.24

544.92

-162.68

-29.85%

Other Income

24.97

27.86

-2.89

-10.37%

Operating Profit (PBDIT)

407.21

572.78

-165.57

-28.91%

Interest

5.10

19.61

-14.51

-73.99%

Exceptional Items

0.00

-58.26

58.26

100.00%

Gross Profit (PBDT)

402.11

494.91

-92.80

-18.75%

Depreciation

43.51

103.33

-59.82

-57.89%

Profit Before Tax

358.60

391.58

-32.98

-8.42%

Tax

84.83

108.08

-23.25

-21.51%

Provisions and contingencies

0.00

Profit After Tax

273.77

283.50

-9.73

-3.43%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

273.77

283.50

-9.73

-3.43%

Share in Profit of Associates

0.00

-2.97

2.97

100.00%

Minority Interest

0.00

-2.04

2.04

100.00%

Other related items

0.00

Consolidated Net Profit

273.77

282.57

-8.80

-3.11%

Equity Capital

25.07

25.37

-0.30

-1.18%

Face Value

2.00

1.00

0.00

Reserves

0.00

Earnings per share (EPS)

21.84

11.14

10.70

96.05%

Diluted Earnings per share

21.91

11.14

10.77

96.68%

Operating Profit Margin (Excl OI)

27.80%

21.32%

0.00

6.48%

Gross Profit Margin

29.25%

19.36%

0.00

9.89%

PAT Margin

19.91%

11.09%

0.00

8.82%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 1,374.84 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 1.56% vs 3.92% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 19.95% vs 3.71% in Dec 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 273.77 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 5.22% vs 1.90% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 17.56% vs 10.88% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 382.24 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 16.60% vs -6.69% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 19.14% vs 2.15% in Dec 2024

Quarterly - Interest

Interest 5.10 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 50.44% vs -35.55% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -35.52% vs 217.67% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 27.80%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024